Is It Too Late To Consider Johnson & Johnson (JNJ) After A 49.8% One-Year Surge?

• Some investors may be wondering whether Johnson & Johnson’s current share price still offers value, or whether most of the opportunity has already been priced in.
• Over the past year the stock delivered a 49.8% return, with year-to-date gains of 14.6%, even after a 1.8% decline over the last week and a 2.4% decline over the past month.
• Recent coverage has focused on Johnson & Johnson’s position as a major healthcare name and on how sentiment around large pharmaceutical and consumer health companies can influence share prices. This context helps explain why the stock’s strong 1-year and 3-year returns of 49.8% and 71.9% sit alongside a more modest 5-year return of 68.9%.
• On Simply Wall St’s valuation model, Johnson & Johnson scores a 4 out of 6. This invites a closer look at how different valuation methods view the stock and points to an even deeper way to think about value that will be covered at the end of this article.

Johnson & Johnson delivered 49.8% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today’s value.

For Johnson & Johnson, the latest twelve month Free Cash Flow (FCF) is about $19.7b. Analysts have provided explicit FCF estimates out to 2030, with Simply Wall St extending the series further using its 2 Stage Free Cash Flow to Equity model. By 2030, projected FCF stands at $36.4b, with intermediate annual projections between 2026 and 2035 ranging from around $25.1b to $45.9b before discounting.

After discounting all those projected cash flows back to today, the model arrives at an estimated intrinsic value of $383.00 per share. This implies an intrinsic discount of 38.0% relative to the current share price, which suggests the stock is trading at a meaningful gap to this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 38.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson.

Approach 2: Johnson & Johnson Price vs Earnings

For a profitable company like Johnson & Johnson, the P/E ratio is a practical way to see how much investors are paying for each dollar of current earnings. It ties the share price directly to earnings, which are usually a key anchor for long term returns.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk often supports a higher P/E, while slower growth or higher risk tends to justify a lower one.

Johnson & Johnson currently trades on a P/E of 21.35x, compared with the Pharmaceuticals industry average of 16.78x and a peer group average of 23.02x. Simply Wall St’s Fair Ratio for Johnson & Johnson is 29.62x, which is its proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio can be more tailored than a simple industry or peer comparison, because it tries to reflect the company’s own characteristics rather than broad group averages. With the current P/E of 21.35x sitting below the Fair Ratio of 29.62x, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, a simple tool on Simply Wall St’s Community page that lets you write the story you believe about Johnson & Johnson and link that story to explicit forecasts for future revenue, earnings, margins and a Fair Value that you can then compare directly to today’s share price.

Instead of only relying on one DCF or a single P/E multiple, a Narrative asks you to set out why you think the business will evolve in a certain way, ties that view to numbers in a full forecast, then automatically updates that Fair Value when new data such as earnings, guidance or news arrives. In this way your decision framework stays current without you rebuilding a model from scratch.

Looking at existing Johnson & Johnson Narratives on Simply Wall St shows how views can differ. One investor estimates Fair Value at about US$246.46 per share, while another is closer to US$133. This gives you a clear, side by side sense of how different assumptions about growth, margins, litigation risk or MedTech potential translate into very different conclusions about whether the current price looks high or low for your own approach.

For Johnson & Johnson, however, we will make it really easy for you with previews of two leading Johnson & Johnson Narratives:

🐂 Johnson & Johnson Bull Case

Fair Value: US$265.00

Gap to Fair Value: 10.4% discount versus the recent share price of US$237.60

Revenue Growth Assumption: 7.1% per year

• Backs a broad set of pharmaceutical and MedTech platforms, each already generating at least US$1b in annual revenue, as the foundation for future sales and earnings.
• Builds in heavy R&D and acquisition spending, along with a large late stage pipeline and complex therapies, as key supports for future products and margins.
• Accepts meaningful risks around patent expiries, pricing pressure, higher costs, acquisitions and litigation, yet still arrives at a bullish Fair Value of US$265 that is above the current share price.

🐻 Johnson & Johnson Bear Case

Fair Value: US$173.55

Gap to Fair Value: 36.9% premium versus the recent share price of US$237.60

Revenue Growth Assumption: 6.3% per year

• Assumes Johnson & Johnson grows revenue from a post spin off baseline, helped by a large late stage drug pipeline and higher margin mix in pharmaceuticals and MedTech.
• Factors in continued dividends and sizeable buybacks funded from earnings, with an assumed future P/E of 22x reflecting the author’s view of what the business could justify.
• Highlights litigation exposure, patent expiries and the uncertainty of drug approvals as key reasons why the implied Fair Value of US$173.55 sits below the current share price.

Do you think there’s more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com